Circulating Tumour Cells in Prostate Cancer Patients Receiving Salvage Radiotherapy

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2012 Feb 4

PMID 22301405

Citations 19

Authors

Lori E Lowes

Michael Lock

George Rodrigues

David DSouza

Glenn Bauman

Belal Ahmad

Varagur Venkatesan

Alison L Allan

Tracy Sexton

Affiliations

Soon will be listed here.

Abstract

Introduction: Within 10 years of radical prostatectomy (RP), up to 30% of prostate cancer (PCa) patients will have a rise in prostate-specific antigen (PSA), requiring radiation therapy (RT). However, with current technology, distinction between local and distant recurrent PCa is not possible. This lack of an accurate test constrains the decision whether to offer systemic or local treatment. We hypothesise tests for detecting circulating tumour cells (CTCs) within the blood may assist with clinical decision-making and in this pilot study we investigated whether CTCs could be detected in this patient population using the CellSearch® system.

Materials And Methods: Blood samples were collected from PCa patients (n=26) prior to RT and 3 months following completion of RT. Samples were analysed for PSA level via immunoassay and CTC number using the CellSearch® system.

Results: CTCs could be detected in this patient population and following RT CTCs appeared to decrease. However, no association was observed between a higher PSA and an increased number of CTCs pre- or post-RT. Interestingly, patients who failed RT trended toward an increased/ unchanged number of CTCs following RT vs. a decreased number in patients with RT response.

Conclusions: Our results demonstrate that CTCs can be detected in early-stage PCa and suggest the possibility that post-treatment reduction in CTC levels may be indicative of RT response . We are currently evaluating CTCs in a larger cohort of patients to validate our preliminary findings and further investigate the prognostic value of CTCs in this patient population.

Citing Articles

Particle Beam Radiobiology Status and Challenges: A PTCOG Radiobiology Subcommittee Report.

Ahmad R, Barcellini A, Baumann K, Benje M, Bender T, Bragado P Int J Part Ther. 2024; 13:100626.

PMID: 39258166 PMC: 11386331. DOI: 10.1016/j.ijpt.2024.100626.

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer.

Rzhevskiy A, Kapitannikova A, Butnaru D, Shpot E, Joosse S, Zvyagin A Biomedicines. 2022; 10(12).

PMID: 36551871 PMC: 9776104. DOI: 10.3390/biomedicines10123115.

Circulating tumor cells in the early detection of human cancers.

Feng Z, Wu J, Lu Y, Chan Y, Zhang C, Wang D Int J Biol Sci. 2022; 18(8):3251-3265.

PMID: 35637960 PMC: 9134923. DOI: 10.7150/ijbs.71768.

Improving the diagnosis of prostate cancer by telomerase-positive circulating tumor cells: A prospective pilot study.

Yang Z, Bai H, Hu L, Kong D, Li G, Zhao C EClinicalMedicine. 2022; 43:101161.

PMID: 35128360 PMC: 8808177. DOI: 10.1016/j.eclinm.2021.101161.

Does Direct and Indirect Exposure to Ionising Radiation Influence the Metastatic Potential of Breast Cancer Cells.

Kadhim M, Mayah A, Brooks S Cancers (Basel). 2020; 12(1).

PMID: 31963587 PMC: 7016586. DOI: 10.3390/cancers12010236.

References

Yoshimoto M, Cunha I, Coudry R, Fonseca F, Torres C, Soares F . FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007; 97(5):678-85. PMC: 2360375. DOI: 10.1038/sj.bjc.6603924. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Tomlins S, Mehra R, Rhodes D, Smith L, Roulston D, Helgeson B . TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006; 66(7):3396-400. DOI: 10.1158/0008-5472.CAN-06-0168. View

Zegarra-Moro O, Schmidt L, Huang H, Tindall D . Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002; 62(4):1008-13. View

Tombal B, Van Cangh P, Loric S, Gala J . Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate. 2003; 56(3):163-70. DOI: 10.1002/pros.10237. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Pound C, Partin A, Epstein J, Walsh P . Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997; 24(2):395-406. DOI: 10.1016/s0094-0143(05)70386-4. View

Stephenson A, Scardino P, Kattan M, Pisansky T, Slawin K, Klein E . Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25(15):2035-41. PMC: 2670394. DOI: 10.1200/JCO.2006.08.9607. View

10.

Lee A, DAmico A . Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol. 2005; 23(32):8192-7. DOI: 10.1200/JCO.2005.03.0007. View

11.

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

12.

Ohori M, Goad J, Wheeler T, Eastham J, Thompson T, Scardino P . Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?. J Urol. 1994; 152(5 Pt 2):1843-9. DOI: 10.1016/s0022-5347(17)32398-4. View

13.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

14.

Maier J, Forman J, Tekyi-Mensah S, Bolton S, Patel R, Pontes J . Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol. 2004; 22(1):50-6. DOI: 10.1016/j.urolonc.2003.12.001. View

15.

Chalasani V, Iansavichene A, Lock M, Izawa J . Salvage radiotherapy following radical prostatectomy. Int J Urol. 2008; 16(1):31-6. DOI: 10.1111/j.1442-2042.2008.02144.x. View

16.

Allan A, Keeney M . Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol. 2010; 2010:426218. PMC: 2798617. DOI: 10.1155/2010/426218. View

17.

Davis J, Nakanishi H, Kumar V, Bhadkamkar V, McCormack R, Fritsche H . Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008; 179(6):2187-91. DOI: 10.1016/j.juro.2008.01.102. View

18.

Lilja H, Ulmert D, Vickers A . Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008; 8(4):268-78. DOI: 10.1038/nrc2351. View

19.

Pantel K, Brakenhoff R, Brandt B . Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008; 8(5):329-40. DOI: 10.1038/nrc2375. View

20.

Mostert B, Sleijfer S, Foekens J, Gratama J . Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009; 35(5):463-74. DOI: 10.1016/j.ctrv.2009.03.004. View